mpact is the name of the p3 trial that showed adding abraxane to gemcitabine increased median survival over gemcitabine by itself. It’s published. Yes abraxane was approved in pancreatic cancer based on mpact.
- Forums
- ASX - By Stock
- Ann: Update on ACCENT Trial in Pancreatic Cancer
mpact is the name of the p3 trial that showed adding abraxane to...
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.38M |
Open | High | Low | Value | Volume |
6.3¢ | 6.4¢ | 6.3¢ | $3.016K | 47.79K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 217306 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.4¢ | 37701 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 217306 | 0.062 |
1 | 122950 | 0.061 |
3 | 39253 | 0.060 |
3 | 108326 | 0.059 |
3 | 100991 | 0.058 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 37701 | 1 |
0.070 | 12509 | 2 |
0.075 | 335646 | 1 |
0.079 | 3000 | 1 |
0.080 | 200000 | 1 |
Last trade - 15.59pm 18/07/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |